In the context of CKD, PXR-activation confers protective functions against kidney damage, while a diminished PXR activation might reduce the expression of drug-metabolising enzymes, changing the pharmacokinetics in CKD [50,51]. This evidence concerns the gene NR1I2 and chronic kidney disease.